IP Verse

Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-Olate - EP3321270

EP3321270

GILEAD SCIENCES
Application Number
EP17204116A
Filing Date
Jun 19, 2015
Status
Granted And Under Opposition
Nov 1, 2024
Grant Date
Dec 4, 2024
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3321270B1 was granted to Gilead Sciences on Dec 4, 2024 following the initial filing on Jun 19, 2015 under the application number EP17204116A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BRAND MURRAY FULLERSep 4, 2025ADMISSIBLE
ELKINGTON AND FIFESep 4, 2025ADMISSIBLE
KRAUS & LEDERER PARTGMBBSep 3, 2025ADMISSIBLE
SANDOZSep 3, 2025ADMISSIBLE
HAMM & WITTKOPPSep 2, 2025ADMISSIBLE

Patent Citations (28) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2013US76367-
DESCRIPTIONUS2013165489
DESCRIPTIONUS2014221378
DESCRIPTIONUS2014221380
DESCRIPTIONWO2004096286
DESCRIPTIONWO2006015261
DESCRIPTIONWO2006110157
DESCRIPTIONWO2009062285
DESCRIPTIONWO2010130034
DESCRIPTIONWO2012003497
DESCRIPTIONWO2012003498
DESCRIPTIONWO2012145728
DESCRIPTIONWO2013006738
DESCRIPTIONWO2013006792
DESCRIPTIONWO2013091096
DESCRIPTIONWO2013159064
DESCRIPTIONWO2014100323
OPPOSITIONEP1874117
OPPOSITIONEP2465580
OPPOSITIONEP2822954
OPPOSITIONEP3157932
OPPOSITIONUS2014221355
OPPOSITIONWO2006116764
OPPOSITIONWO2011119566
OPPOSITIONWO2014100323
OTHEREP3157932
SEARCHEP2465580
SEARCHWO2014100323

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- PATELLA et al., N. Engl. J Med., (19980000), vol. 338, page 853,860-
DESCRIPTION- RICHMAN, D. D., Nature, (20010000), vol. 410, pages 995 - 1001-
OPPOSITION- Anonymous, "Assessment report Biktarvy (EMA/293559/2018)", Assessment report Biktarvy, European Medicines Agency, pages 1 - 104, Assessment report Biktarvy, URL: https://www.ema.europa.eu/en/documents/assessment-report/biktarvy-epar-public-assessment-report_en.pdf, XP093312858-
OPPOSITION- Anonymous, "Assessment report Tivicay: EMA/CHMP/772068/2013 ", Assessment report Tivicay, European Medicines Agency, pages 1 - 102, Assessment report Tivicay, URL: https://www.ema.europa.eu/en/documents/assessment-report/tivicay-epar-public-assessment-report_en.pdf, XP093312884-
OPPOSITION- Anonymous, "Guideline on the chemistry of active substances", EUROPEAN MEDICINES AGENCY; EMA/CHMP/QWP/96664/2015 Committee for Medicinal Products for Human Use (CHMP), EUROPEAN MEDICINES AGENCY; EMA/CHMP/QWP/96664/2015 Committee for Medicinal Products for Human Use (CHMP) , (20240305), XP093137935-
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN) , Proposed INN: List 113 ", WHO DRUG INFORMATION, GENEVA, CH, CH , (20150609), vol. 29, no. 2, ISSN 1010-9609, pages 195 - 301, XP093312899-
OPPOSITION- Camille G. Wermuth, P. Heinrich Stahl, "Chapter 12: Selected Procedures for the Preparation of Pharmaceutically Acceptable Salts", Camille G. Wermuth, P. Heinrich Stahl, Stahl, Wermuth, Handbook of Pharmaceutical Salts Properties, Selection, and Use, Wiley-VCH, (20110101), vol. 2, pages 307 - 325, ISBN 3-906390-51-9, XP009562938-
OPPOSITION- D15a - Publication date of TM4-
OPPOSITION- D3b - EPO register for WO 2014/100323-
OPPOSITION- D6 - Letter of the applicant dated June 9, 2015 to the EPO (EP 2 822 954)-
OPPOSITION- James Wells, "Chapter 8: Pharmaceutical preformulation: the physicochemical properties of drug substances", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, UK, Elsevier , (20020101), pages 113 - 138, ISBN 0-443-05517-3, XP055294349-
OPPOSITION- BERGE S. M., BIGHLEY L. D., MONKHOUSE D. C., "Pharmaceutical Salts", Journal of pharmaceutical sciences, Elsevier Inc, (19770101), vol. 66., no. 01., doi:10.1002/jps.2600660104, ISSN 0022-3549, pages 01 - 19., XP000562636
OPPOSITION- Xiaorong He, "Chapter 18 - Integration of Physical, Chemical, Mechanical, and Biopharmaceutical Properties in Solid Oral Dosage Form Development", Xiaorong He, Qiu Yihong, Developing solid oral dosage forms : pharmaceutical theory and practice, Burlington, MA, USA , Elsevier/Academic Press , (20081224), pages 409 - 441, doi:10.1016/B978-0-444-53242-8.00018-7, ISBN 978-0-444-53242-8, XP009553797
OPPOSITION- Serajuddin, A.T.M., "Salt formation to improve drug solubility", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (20070824), vol. 59, no. 7, doi:10.1016/j.addr.2007.05.010, ISSN 0169-409X, pages 603 - 616, XP022211982
OPPOSITION- Chappa Praveen, Jenjeti Ramesh Naidu, Kljun Jakob, Mittapalli Sudhir, Pichler Arthur, Desiraju Gautam R., "Pharmaceutical Solid Form Screening and Selection: Which Form Emerges?", Crystal Growth & Design, ASC Washington DC, US, US , (20250702), vol. 25, no. 13, doi:10.1021/acs.cgd.5c00252, ISSN 1528-7483, pages 4783 - 4794, XP093312906
OPPOSITION- Brittain Harry G, "Chapter 1: Theory and Principles of Polymorphic Systems", Brittain Harry G, Brittain Harry G., Polymorphism in Pharmaceutical Solids, Second Edition, Informa healthcare , (20090727), pages 1 - 23, doi:10.3109/9781420073225, ISBN 978-1-4200-7321-8, XP093312919

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents